This draft guidance document for industry and FDA staff describes the Food and Drug Administration's proposed program to evaluate a globally harmonized alternative for premarket procedures. The program is intended to assess the feasibility of an internationally harmonized format and content for premarket submissions, e.g., premarket notification (510(k))submissions and premarket approval (PMA) applications. The following is a link to the complete set of documents.
http://www.fda.gov/cdrh/ode/guidance/1347.htmlFDA's proposed 'globally harmonized' PMA alternative
Jul 24, 2001
Latest in Regulatory
FDA rejects NDA for Telix’s Pixclara
April 29, 2025
Health data restrictions plague medtech AI developers
April 23, 2025
Cortechs.ai software gets Health Canada approval
April 22, 2025
DESKi granted FDA clearance for cardiac AI software
April 15, 2025